About lana delu mab
Plasma kallikrein inhibitor monoclonal antibody
Used for
- Prevents hereditary angioedema attacks in adults and children aged 2 years and older.
Usual adult dose
300 mg under the skin every 2 weeks; some well-controlled patients may use every 4 weeks.
Usual dose in children
Age 2–11: 150 mg every 2 weeks if under 40 kg; 300 mg every 2 weeks if 40 kg or more. Age 12–17: 300 mg every 2 weeks; some well-controlled patients may use every 4 weeks.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Headache
- Muscle pain
Important warnings
- Not for treating an acute hereditary angioedema attack.
- Severe allergic reactions, including anaphylaxis, can occur.
- Patients should retain access to their prescribed acute-attack treatment.
Pregnancy
Human pregnancy data are limited; use only when the expected benefit justifies potential fetal risk.
Breastfeeding
It is not known whether lanadelumab passes into breast milk; consider benefits and potential risks.
Interactions
- No clinically significant drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.